Europe Multiple Sclerosis Therapeutics Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Europe Multiple Sclerosis Therapeutics Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Europe Multiple Sclerosis Therapeutics Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Europe Multiple Sclerosis Therapeutics Market Regional Analysis

6.2 Europe Multiple Sclerosis Therapeutics Market Revenue 2017-2027 (US$ Million)

6.3 Europe Multiple Sclerosis Therapeutics Market Forecast Analysis

7. Europe Multiple Sclerosis Therapeutics Market Analysis – by Drug Class

7.1 Immunosuppressant

7.1.1 Overview
7.1.2 Immunosuppressant: Europe Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

7.2 Immunomodulators

7.2.1 Overview
7.2.2 Immunomodulators: Europe Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8. Europe Multiple Sclerosis Therapeutics Market Analysis – by Route of Administration

8.1 Injectable

8.1.1 Overview
8.1.2 Injectable: Europe Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.2 Oral

8.2.1 Overview
8.2.2 Oral: Europe Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

9. Europe Multiple Sclerosis Therapeutics Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies

9.1.1 Overview
9.1.2 Hospital Pharmacies: Europe Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

9.2 Retail Pharmacies

9.2.1 Overview
9.2.2 Retail Pharmacies: Europe Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

9.3 E-Commerce

9.3.1 Overview
9.3.2 E-Commerce : Europe Multiple Sclerosis Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

10. Europe Multiple Sclerosis Therapeutics Market – Europe Analysis

10.1 Overview

10.2 Europe

10.2.1 Europe Multiple Sclerosis Therapeutics Market Breakdown, by Key Country, 2020 and 2027 (%)
10.2.1.1 Europe Multiple Sclerosis Therapeutics Market – Revenue and Forecast Analysis – by Country
10.2.1.1 UK: Europe Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.1.1 UK: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
10.2.1.1.2 UK: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
10.2.1.1.3 UK: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel

10.2.1.2 Germany: Europe Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.2.1 Germany: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
10.2.1.2.2 Germany: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
10.2.1.2.3 Germany: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel

10.2.1.3 France: Europe Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.3.1 France: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
10.2.1.3.2 France: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
10.2.1.3.3 France: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel

10.2.1.4 Russia: Europe Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.4.1 Russia: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
10.2.1.4.2 Russia: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
10.2.1.4.3 Russia: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel

10.2.1.5 Italy: Europe Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.5.1 Italy: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
10.2.1.5.2 Italy: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
10.2.1.5.3 Italy: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel

10.2.1.6 Rest of Europe: Europe Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.6.1 Rest of Europe: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Drug Class
10.2.1.6.2 Rest of Europe: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Route of Administration
10.2.1.6.3 Rest of Europe: Europe Multiple Sclerosis Therapeutics Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview

12.2 Market Initiative

12.3 Partnerships and Collaborations

12.4 Other Developments

13. Company Profiles

13.1 Merck & Co., Inc.

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Novartis AG

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Bayer AG

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Sanofi

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Bristol-Myers Squibb Company

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Horizon Therapeutics plc

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 TEVA PHARMACEUTICAL INDUSTRIES LTD

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Takeda Pharmaceutical Company Limited

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 F. HOFFMANN-LA ROCHE LTD

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Biogen

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

14.2 List of Abbreviations

Europe Multiple Sclerosis Therapeutics Market

Analysis By Drug Class (Immunosuppressant and Immunomodulators), Route of Administration (Injectable and Oral), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce)